Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread

23 Feb 2023

Abstract excerpt

Vaccination against human cytomegalovirus (CMV) infection remains high priority. A recombinant form of a protein essential for CMV entry, glycoprotein B (gB), demonstrated partial protection in a clinical trial (NCT00299260) when delivered with the MF59 adjuvant. Although the antibody titre against gB correlated with protection poor neutralising responses against the 5 known antigenic domains (AD) of gB were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytomegalovirus and herpesvirus research
Share to Herpesvirus Infections and Treatments
Share to Mosquito-borne diseases and control

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36823200
DOI: 10.1038/s41467-023-36683-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spreadPMID 36823200Read ↗

Vaccination with a disabled infectious single cycle cytomegalovirus vaccine elicits a distinct glycoprotein B-specific monoclonal antibody repertoire compared to that of naturally-infected individualsSemantic proximity Read ↗

Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humansSemantic proximity Read ↗

Specificity and effector functions of non-neutralizing gB-specific monoclonal antibodies isolated from healthy individuals with human cytomegalovirus infectionSemantic proximity Read ↗

Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.Semantic proximity Read ↗

HCMV glycoprotein B subunit vaccine efficacy was mediated by non-neutralizing antibody effector functionsSemantic proximity Read ↗

Crystal Structure of the Human Cytomegalovirus Glycoprotein BSemantic proximity Read ↗

Recombinant cytomegalovirus glycoprotein B vaccine: Rethinking the immunological basis of protectionSemantic proximity Read ↗

Structural Basis for the Recognition of Human Cytomegalovirus Glycoprotein B by a Neutralizing Human AntibodySemantic proximity Read ↗

Virion Glycoprotein-Mediated Immune Evasion by Human Cytomegalovirus: a Sticky Virus Makes a Slick GetawaySemantic proximity Read ↗

HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functionsSemantic proximity Read ↗

Cell Fusion Induced by a Fusion-Active Form of Human Cytomegalovirus Glycoprotein B (gB) Is Inhibited by Antibodies Directed at Antigenic Domain 5 in the Ectodomain of gBSemantic proximity Read ↗

A single, improbable B cell receptor mutation confers potent neutralization against cytomegalovirusSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.